|
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 94.32 USD | +3.74% |
|
+2.30% | +103.10% |
| Capitalization | 6.38B 8.6B 7.46B 7.02B 11.81B 745B 13.3B 83.18B 31.83B 341B 32.26B 31.57B 1,254B | P/E ratio 2025 * |
184x | P/E ratio 2026 * | 37.1x |
|---|---|---|---|---|---|
| Enterprise value | 6.24B 8.41B 7.29B 6.87B 11.55B 728B 13.01B 81.36B 31.14B 334B 31.55B 30.88B 1,227B | EV / Sales 2025 * |
20.2x | EV / Sales 2026 * | 11.2x |
| Free-Float |
68.7% | Yield 2025 * |
-
| Yield 2026 * | - |
More valuation ratios
* Estimated data
More news
Last Transcript: Verona Pharma plc
More recommendations
More press releases
| 1 day | +3.74% | ||
| 1 week | +2.30% | ||
| Current month | +16.16% | ||
| 1 month | +27.30% | ||
| 3 months | +41.18% | ||
| 6 months | +124.46% | ||
| Current year | +103.10% |
| 1 week | 89.69 |  | 94.45 |
| 1 month | 71 | | 94.45 |
| Current year | 43.44 | | 94.45 |
| 1 year | 14.14 | | 94.45 |
| 3 years | 3.99 | | 94.45 |
| 5 years | 3.41 | | 94.45 |
| 10 years | 0 | | 94.45 |
| Manager | Title | Age | Since |
|---|---|---|---|
| Chief Executive Officer | 60 | 2020-01-31 | |
Mark Hahn
DFI | Director of Finance/CFO | 62 | 2020-02-29 |
Kavita Aggarwal
CTO | Chief Tech/Sci/R&D Officer | - | 2022-12-31 |
| Director | Title | Age | Since |
|---|---|---|---|
David Ebsworth
CHM | Chairman | 70 | 2014-11-30 |
| Director/Board Member | 72 | 2015-09-09 | |
| Director/Board Member | 69 | 2015-09-09 |
| Change | 5d. change | 1-year change | 3-years change | Capi.($) | ||
|---|---|---|---|---|---|---|
| +3.74% | +2.30% | +528.80% | +2,349.87% | 8.6B | ||
| -0.75% | -3.69% | -51.60% | -13.26% | 53.86B | ||
| -0.44% | -6.27% | +26.71% | +39.26% | 33.16B | ||
| +0.52% | -4.39% | +61.20% | -33.18% | 26.05B | ||
| +2.04% | -0.04% | +25.86% | -13.57% | 26.23B | ||
| +3.24% | +4.00% | +51.02% | +429.82% | 19.5B | ||
| +1.98% | +3.94% | +159.27% | +1,956.00% | 15.27B | ||
| -1.78% | -7.02% | -23.75% | -34.58% | 13.11B | ||
| 0.00% | -13.93% | +107.76% | -66.10% | 12.49B | ||
| -0.91% | -2.93% | +81.85% | +108.63% | 11.01B | ||
| Average | +0.76% | -2.83% | +96.71% | +472.29% | 21.93B | |
| Weighted average by Cap. | +0.48% | -3.05% | +46.92% | +263.29% |
| 2025 * | 2026 * | |
|---|---|---|
| Net sales | 310M 417M 362M 341M 573M 36.14B 646M 4.04B 1.55B 16.56B 1.57B 1.53B 60.87B | 548M 738M 640M 603M 1.01B 63.91B 1.14B 7.14B 2.73B 29.28B 2.77B 2.71B 108B |
| Net income | 16.89M 22.76M 19.74M 18.59M 31.25M 1.97B 35.21M 220M 84.26M 903M 85.38M 83.57M 3.32B | 178M 240M 208M 196M 329M 20.75B 371M 2.32B 887M 9.51B 899M 880M 34.94B |
| Net Debt | -139M -187M -162M -153M -257M -16.21B -290M -1.81B -693M -7.42B -702M -687M -27.29B | -248M -334M -290M -273M -459M -28.95B -517M -3.23B -1.24B -13.26B -1.25B -1.23B -48.76B |
More financial data
* Estimated data
Employees
209
Calendar
| Date | Price | Change | Volume |
|---|---|---|---|
| 25-06-20 | 94.32 $ | +3.74% | 1,089,843 |
| 25-06-18 | 90.92 $ | -2.16% | 1,008,667 |
| 25-06-17 | 92.93 $ | +0.25% | 1,158,927 |
| 25-06-16 | 92.70 $ | +0.54% | 974,611 |
| 25-06-13 | 92.20 $ | -0.32% | 754,465 |
Delayed Quote Nasdaq, June 20, 2025 at 04:00 pm EDT
More quotes
Sell
Buy
Mean consensus
BUY
Number of Analysts
10
Last Close Price
94.32USD
Average target price
103.10USD
Spread / Average Target
+9.31%
Quarterly revenue - Rate of surprise
- Stock Market
- Equities
- VRNA Stock
Select your edition
All financial news and data tailored to specific country editions
